5 Key Takeaways
-
1
VOY-101 is a novel gene therapy targeting geographic atrophy (GA) through complement regulation, currently in phase 2 testing.
-
2
The therapy aims to restore complement regulation by delivering a protective complement factor H protein to patients with GA.
-
3
Phase 1 studies showed VOY-101 had a well-tolerated safety profile, with no serious adverse events or dose-limiting toxicities reported.
-
4
Transgene expression was significantly elevated, with levels up to 13-fold above baseline observed in the highest dose cohorts.
-
5
The ongoing phase 2 JOURNEY trial uses a fellow-eye control design to evaluate VOY-101's efficacy in reducing GA lesion growth.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.